Back to the beginning: Pfizer seeds discovery-stage neuro startup Magnolia (after axing its own brain R&D)
After yanking its own neuroscience efforts — and retreating from the failure-strewn battleground of brain science — Pfizer is pedaling back to the beginning in this field. The pharma giant is funding a brand-new MD Anderson spinout that’s questioning the very basics of neurodegeneration.
The startup, called Magnolia Neurosciences (“Magnolia” as a nod to its Texas roots), is being rather tightlipped about what it’s working on. But CEO Thong Le tells me the company is steering away from traditional efforts in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.